October 31st 2024
The partnership will use ViaNautis’ proprietary polyNaut technology platform to develop genetic medicines that can precisely target tissue types.
May 24th 2024
With this acquisition, Merck KGaA will have the capability to offer integrated services for viral vector manufacturing.
May 7th 2024
The two companies will combine their cell therapy platforms to develop convertibleCAR programs targeting solid tumors.
April 16th 2024
The LNP success in mRNA vaccines leads to their establishment as a standard in mRNA delivery.
April 11th 2024
Charles River has entered into separate agreements with Axovia Therapeutics and Ship of Theseus to offer plasmid DNA manufacturing services for a gene therapy and a lead candidate program, respectively.